Triple-negative breast cancer

About triple-negative breast cancer

Breast cancer is the most common cancer diagnosis in women worldwide (Source: World Cancer Research Fund) and is the cancer that causes the largest number of deaths. Triple-negative breast cancer is an aggressive form of the disease, characterized by the absence of estrogen and progesterone receptors and not involving overexpression of human epidermal growth factor 2 (HER2).

Because of a lack of specific receptors, triple-negative breast cancer is usually treated with surgery, radiotherapy and chemotherapy. In early 2018, a first PARP inhibitor was approved by the FDA; it will be available for treatment of the approximately 10 percent of patients suffering from triple negative breast cancer that test positive for BRCA mutation. In addition, several immuno-oncology drugs are under development with Atezolizumab, which recently was approved as first-line treatment in combination with Abraxane.

Judging by how TNBC responds to other targeted therapies and the success rate of immuno-oncology agents in other cancer indications, it is clear that the need for innovation will remain strong in this area as well. Thus, Coegin Pharma may either position itself for TNBC patients on its own, or, alternatively, as a component of combination therapies including other substances, such as PI-3K inhibitors, to meet the high demand for innovation.

Market overview

The sale of breast cancer therapies will increase from USD 9.8 billion in 2013 to USD 18.2 billion in 2023 (Source: IMS Health). Datamonitor Healthcare estimates that there were 2.1 million breast cancer cases worldwide in 2018, and that the five-year prevalence was 8.6 million. By 2027, incident and prevalent cases of breast cancer are expected to increase to 2.3 million and 9.3 million respectively.